For the quarter ending 2025-09-30, OTLC has $28,156,163 in assets. $20,079,663 in debts. $409,000 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 409,000 | 88,022 | ||
| Restricted cash | 20,000 | 20,000 | ||
| Accounts receivable | 3,976 | 18,976 | ||
| Prepaid & other current assets | 1,179,972 | 10,594 | ||
| Total current assets | 1,612,948 | 137,592 | ||
| In process r&d | 1,101,760 | 1,101,760 | ||
| Goodwill, net of impairment | 2,788,230 | 2,788,230 | ||
| Investment in gmp bio at fair value | 22,653,225 | 22,653,225 | ||
| Total assets | 28,156,163 | 26,680,807 | ||
| Accounts payable and accrued liabilities | 2,565,877 | 2,487,234 | ||
| Accounts payable - related party-Related Party | 347,598 | 347,084 | ||
| Contingent consideration | 2,625,000 | 2,625,000 | ||
| Derivative liability on notes | 670,844 | 278,786 | ||
| Convertible debt-Nonrelated Party | 10,328,100 | 9,940,174 | ||
| Convertible debt-Related Party | 3,542,244 | 3,608,634 | ||
| Total current liabilities | 20,079,663 | 19,286,912 | ||
| Total liabilities | 20,079,663 | 19,286,912 | ||
| Common stock, .01 par value 750,000,000 shares authorized 439,446,318 and 407,289,618 issued and outstanding, respectively (note 11) | 4,394,463 | 4,082,927 | ||
| Additional paid-in capital | 43,765,008 | 42,279,570 | ||
| Accumulated deficit | -39,108,893 | -38,061,528 | ||
| Total oncotelic therapeutics, inc. stockholders equity | 9,050,578 | 8,300,969 | ||
| Non-controlling interests | -974,078 | -907,074 | ||
| Total stockholders equity | 8,076,500 | 7,393,895 | ||
| Total liabilities and stockholders equity | 28,156,163 | 26,680,807 | ||
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. (OTLC)